Arrowhead Pharmaceuticals Inc. (ARWR) is a multinational biopharmaceutical company based in Pasadena, California. Its primary focus is on developing medicines that can ideally treat intractable diseases by silencing the genes responsible for them. Known for their pioneering spirit and innovative solutions, ARWR's mission is to fight severe and genetically determined diseases at the molecular level, offering hope to millions of patients worldwide.
The company is at the forefront of the scientific world, working diligently to develop RNA interference (RNAi) therapeutics. RNAi is a natural process that cells use to turn off genes and an approach that has the potential to create therapies for diseases that are hard to treat using traditional methods. By using this innovative technological strategy, ARWR's products have the potential to provide effective, new and innovative solutions to individuals suffering from debilitating chronic illnesses or genetically correlated diseases.
Arrowhead is relentlessly striving to become a pioneer in RNAi-based therapeutics, maintaining a deep pipeline of “RNAi” drugs for a range of diseases including liver diseases, cardiovascular diseases, respiratory conditions, and chronic hepatitis B infections. Some of its leading products include ARO-AAT, designed to treat liver disease associated with alpha-1 antitrypsin deficiency, and ARO-APOC3, a treatment for hypertriglyceridemia.
ARWR has several partnerships with industry leaders to help speed their therapies to the market by leveraging their expertise in RNAi delivery and drug development. For instance, Arrowhead teamed up with Johnson & Johnson's subsidiary, Janssen Pharmaceuticals, to work on their ARO-HBV drug, which is designed to treat chronic hepatitis B.
Since its establishment, Arrowhead Pharmaceuticals has adopted an innovative pharmaceutical development strategy, consistently demonstrating its progressive attitude towards cutting-edge research to combat genetically linked diseases. This strategy has led to its transformation into a highly reputable institution in the biotechnology industry. The company’s continued commitment to innovation and its targeted approach to tackling complex genetic disorders make it a valuable contributor to global medical advancements.